A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

The Sequence Alignment/Map format and SAMtools

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724

Fast and accurate long-read alignment with Burrows-Wheeler transform.

Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Artificial intelligence aids in development of nanomedicines for cancer management

Tan, P., Chen, X., Zhang, H., Wei, Q., & Luo, K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.005 · Cited by 256

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2 -deficient Mesothelioma

Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245

Coordinating gene expression during the cell cycle

Fischer, M., Schade, A. E., Branigan, T. B., Müller, G. A., & DeCaprio, J. A. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.06.007 · Cited by 218

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215

Insights into recent findings and clinical application of YAP and TAZ in cancer

Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors

Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 171

The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., & Ma, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637675 · Cited by 184

Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer

Zhang, K.-R., Zhang, Y.-F., Lei, H.-M., Tang, Y., Ma, C., Lv, Q.-M., Wang, S.-Y., Lu, L., Shen, Y. H., Chen, H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg6428 · Cited by 149

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Patel, S. A., Nilsson, M. B., Yang, Y., Le, X., Tran, H. T., Elamin, Y. Y., Yu, X., Zhang, F., Poteete, A., Ren, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3379 · Cited by 123

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120

Targeted Drug/Gene/Photodynamic Therapy via a Stimuli‐Responsive Dendritic‐Polymer‐Based Nanococktail for Treatment of EGFR‐TKI‐Resistant Non‐Small‐Cell Lung Cancer

Huang, J., Zhuang, C., Chen, J., Chen, X., Li, X., Zhang, T., Wang, B., Feng, Q., Zheng, X., Gong, M., et al. (2022) · Advanced Materials · doi:10.1002/adma.202201516 · Cited by 116

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 112

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 112

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer

Haderk, F., Chou, Y., Čech, L., Fernández-Méndez, C., Yu, J. X., Olivas, V. R., Meraz, I. M., Rabago, D. B., Kerr, D. L., Gómez, C. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47423-0 · Cited by 108

YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner

Chen, H., Yu, Y., Yang, M., Huang, H., Ma, S., Hu, J., Xi, Z., Guo, H., Yao, G., Yang, L. S., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00759-w · Cited by 106

20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight

Singh, S. K., Sadhukhan, S., & Sonawane, A. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188967 · Cited by 109

Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy

Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers

Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 88

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial

Yap, T. A., Kwiatkowski, D. J., Dagogo‐Jack, I., Offin, M. D., Zauderer, M. G., Kratzke, R. A., Desai, J., Body, A. L., Millward, M., Tolcher, A. W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04029-3 · Cited by 91

The role of SOX family transcription factors in gastric cancer

Abadi, A. J., Zarrabi, A., Hashemi, F., Zabolian, A., Najafi, M., Entezari, M., Hushmandi, K., Aref, A. R., Khan, H. Z., Makvandi, P., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.202 · Cited by 70

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

Santarpía, M., Massafra, M., Gebbia, V., d’Aquino, A., Garipoli, C., Altavilla, G., & Rosell, R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1113 · Cited by 72

Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)

Sun, R., Hou, Z., Zhang, Y., & Jiang, B. (2022) · Oncology Letters · doi:10.3892/ol.2022.13528 · Cited by 77

Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1

Yi, J., Li, H., Chu, B., Kon, N., Hu, X., Hu, J., Xiong, Y., Kanıskan, H. Ü., Jin, J. J., & Gu, W. J. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01180-7 · Cited by 70

Targeting the Hippo pathway in cancer

Harvey, K. F., & Tang, T. T.-L. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01234-0 · Cited by 68

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Li, S., Correia, G. S. D. C., Wang, J., Manochakian, R., Zhao, Y., & Lou, Y. (2023) · Cancers · doi:10.3390/cancers15112899 · Cited by 64

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

Noia, V. D., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., & Ceresoli, G. L. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100280 · Cited by 60

New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer

Zhao, Y., Sheldon, M., Sun, Y., & Ma, L. (2023) · Cancers · doi:10.3390/cancers15235497 · Cited by 63

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.002 · Cited by 85

Therapeutic Targeting of Glutamate Dehydrogenase 1 that Links Metabolic Reprogramming and Snail-Mediated Epithelial-Mesenchymal Transition in Drug-Resistant Lung Cancer

Wang, Q., Wu, M., Li, H., Rao, X., Ao, L., Wang, H., Yao, L., Wang, X., Hong, X., Wang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106490 · Cited by 55

Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment

Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02323-9 · Cited by 60

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Zhang, H., Steed, A., Co, M., & Chen, X. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.32 · Cited by 50

Hippo Signaling at the Hallmarks of Cancer and Drug Resistance

Kumar, R., & Hong, W. (2024) · Cells · doi:10.3390/cells13070564 · Cited by 47

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

Pan, Q., Lu, Y., Li, X., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00792 · Cited by 48

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities

Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 48

FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer

Guan, S., Chen, X., Chen, Y., Xie, W., Liang, H., Xia Shuang, Z. H. U., Yang, Y., Fang, W., Huang, Y., Zhao, H., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0791 · Cited by 45

Role of Mechanotransduction in Periodontal Homeostasis and Disease

Dieterle, M. P., Husari, A., Steinberg, T., Wang, X., Ramminger, I., & Tomakidi, P. (2021) · Journal of Dental Research · doi:10.1177/00220345211007855 · Cited by 43

Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer

Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 49

Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

Yang, H., Sun, B., Xu, K., He, Y., Zhang, T., Hall, S. R. R., Tan, S. T., Schmid, R. A., Peng, R., Hu, G., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103457 · Cited by 44

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma

Yang, H., Hall, S. R. R., Sun, B., Zhao, L., Gao, Y., Schmid, R. A., Tan, S. T., Peng, R., & Yao, F. (2021) · Cancers · doi:10.3390/cancers13071561 · Cited by 43

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

Liang, H., Xu, Y., Zhao, J., Chen, M., & Wang, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00761-z · Cited by 45

Biological insights in non-small cell lung cancer

Rosell, R., Jain, A. S., Codony‐Servat, J., Lewintre, E. J., Morrison, B., Barretina, J., & González‐Cao, M. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0108 · Cited by 39

Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated

Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2022) · Medical Oncology · doi:10.1007/s12032-022-01801-0 · Cited by 40

Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR

Schuhwerk, H., & Brabletz, T. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.009 · Cited by 35

An intelligent hypoxia-relieving chitosan-based nanoplatform for enhanced targeted chemo-sonodynamic combination therapy on lung cancer

Zhang, P., Zhang, L., Wang, J., Zhu, L., Li, Z., Chen, H., & Gao, Y. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118655 · Cited by 36

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyPreprint

Stewart, C. A., Gay, C. M., Ramkumar, K., Cargill, K. R., Cardnell, R. J., Nilsson, M. B., Heeke, S., Park, E. M., Kundu, S. T., Diao, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.28.122291 · Cited by 36

YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer

Ning, Y., Zheng, H., Yang, Y., Zang, H., Wang, W., Zhan, Y., Wang, H., Luo, J., Wen, Q., Peng, J., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.79965 · Cited by 36

RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1

Li, H., Li, Y., Zheng, X., Chen, F., Zhang, S., Xu, S., Mu, Y., Shen, W., Tong, J., Chen, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03220-z · Cited by 38

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity

Xu, D., Yin, S., & Shu, Y. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00627-5 · Cited by 36

Identification, functional insights and therapeutic targeting of EMT tumour states

Dong, A., & Blanpain, C. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00873-0 · Cited by 41

USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Zhang, Z., Liu, W., Bao, X., Sun, T., Wang, J., Li, M., & Liu, C. (2022) · PubMed Central · Cited by 32

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis

Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31

Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition

Paul, S., Hagenbeek, T. J., Tremblay, J., Kameswaran, V., Ong, C. C., Liu, C., Guarnaccia, A. D., Mondo, J. A., Hsu, P., Kljavin, N. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56634-y · Cited by 34

Selective Targeting of Vascular Endothelial YAP Activity Blocks EndMT and Ameliorates Unilateral Ureteral Obstruction-Induced Kidney Fibrosis

Ren, Y., Zhang, Y., Wang, L., He, F., Yan, M., Liu, X., Ou, Y., Wu, Q., Bi, T., Wang, S., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00010 · Cited by 31

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review

Wang, C., Zhang, Y., Zhang, T., Xu, J., Yan, S., Liang, B., & Xing, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127440 · Cited by 31

Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?

Paul, S., Sims, J., Pham, T., & Dey, A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.004 · Cited by 30

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Negrao, M. V., Paula, A. G., Molkentine, D. P., Hover, L. D., Nilsson, M. B., Vokes, N. I., Engstrom, L. D., Calinisan, A., Briere, D. M., Waters, L. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2310 · Cited by 33

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Chen, C., & Liu, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14020130 · Cited by 28

From the Matrix to the Nucleus and Back: Mechanobiology in the Light of Health, Pathologies, and Regeneration of Oral Periodontal Tissues

Dieterle, M. P., Husari, A., Steinberg, T., Wang, X., Ramminger, I., & Tomakidi, P. (2021) · Biomolecules · doi:10.3390/biom11060824 · Cited by 28

FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression

Zhu, J., Zhao, J., Luo, C. H., Zhu, J., Peng, X., Zhu, X., Kang, L., Bu, F., Zhang, W., Li, Q., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04960-0 · Cited by 28

Structure-based discovery of a novel small-molecule inhibitor of TEAD palmitoylation with anticancer activity

Gridnev, A., Maity, S., & Misra, J. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021823 · Cited by 30

Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC

Wang, Y., Zhou, Q., Liu, C., Zhang, R., Xing, B., Du, J., Dong, L., Zheng, J., Chen, Z., Sun, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216612 · Cited by 25

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity

Mahabady, M. K., Mirzaei, S., Saebfar, H., Gholami, M. H., Zabolian, A., Hushmandi, K., Hashemi, F., Tajik, F., Hashemi, M., Kumar, A. P., et al. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30751 · Cited by 24

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma

Shinozaki, T., Togasaki, K., Hamamoto, J., Mitsuishi, A., Fukushima, T., Sugihara, K., Ebisudani, T., Okada, M., Saito, A., Shigematsu, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59623-3 · Cited by 26

ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

Gu, J., Zhong, K., Wang, L., Ni, H., Zhao, Y., Wang, X., Yao, Y., Jiang, L., Wang, B., & Zhu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013035 · Cited by 25

HLF promotes ovarian cancer progression and chemoresistance via regulating Hippo signaling pathway

Han, T., Chen, T., Chen, L., Li, K., Xiang, D., Dou, L., Li, H., & Gu, Y. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06076-5 · Cited by 22

c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression

Wang, W., Shang, Y., Wang, C., Ni, J., Wang, A., Li, G., Su, L., & Chen, S. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00905-7 · Cited by 22

A role for YAP / FOXM1 /Nrf2 axis in oxidative stress and apoptosis of cataract induced by UVB irradiation

Hong, Y., Sun, Y., Ainiwaer, M., Xiao, B., Zhang, S., Ning, L., Zhu, X., & Ji, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202400848r · Cited by 20

Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLC

Mascaux, C., Sen, T., Sánchez‐Céspedes, M., Ortiz‐Cuaran, S., Bossé, Y., Dammeijer, F. F., Cavic, M. R., Barr, M. P., Arulananda, S., Armisén, R., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.024 · Cited by 22

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Padhye, A., Konen, J. M., Rodriguez, B. L., Fradette, J. J., Ochieng, J. K., Diao, L., Wang, J., Lü, W., Solis, L. S., Batra, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148392 · Cited by 22

MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer

Kuthethur, R., Adiga, D., Kandettu, A., Jerome, M. S., Mallya, S. P., Mumbrekar, K. D., Kabekkodu, S. P., & Chakrabarty, S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1131433 · Cited by 20

An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives

Zhang, H., Li, Y., & Liu, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1374264 · Cited by 21

TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC

Tammaccaro, S. L., Prigent, P., Le Bail, J.-C., Dos-Santos, O., Dassencourt, L., Eskandar, M., Buzy, A., Venier, O., Guillemot, J.-C., Veeranagouda, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040553 · Cited by 18

Effects of YAP1 and SFRP2 overexpression on the biological behavior of colorectal cancer cells and their molecular mechanisms

Bai, Z., Wu, Q., Zhang, C., Chen, J., & Cao, L. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-418 · Cited by 18

Licochalcone A Promotes the Ubiquitination of c‐Met to Abrogate Gefitinib Resistance

Han, S., Li, X., Gan, Y., & Li, W. (2022) · BioMed Research International · doi:10.1155/2022/5687832 · Cited by 18

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

Sun, Q., Lü, Z., Zhang, Y., Xue, D., Xia, H., She, J., & Li, F. (2022) · Cells · doi:10.3390/cells11132078 · Cited by 18

DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy

Heo, H., Kim, J.-H., Lim, H. J., Kim, J., Kim, M., Koh, J., Kim, B., Kim, B.-K., Won, M., Park, J.-H., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00836-7 · Cited by 17

AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure

Sui, Y., Shen, Z., Pan, R., Ma, R., Si, R., Feng, J., & Zhou, G. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07650-9 · Cited by 17

Structure and function of MuvB complexes

Müller, G. A., Asthana, A., & Rubin, S. M. (2022) · Oncogene · doi:10.1038/s41388-022-02321-x · Cited by 17

YY2/BUB3 Axis promotes SAC Hyperactivation and Inhibits Colorectal Cancer Progression via Regulating Chromosomal Instability

Hosea, R., Duan, W., Meliala, I. T. S., Li, W., Wei, M., Hillary, S., Zhao, H., Miyagishi, M., Wu, S., & Kasim, V. (2024) · Advanced Science · doi:10.1002/advs.202308690 · Cited by 16

Corosolic acid inhibits EMT in lung cancer cells by promoting YAP-mediated ferroptosis

Zhang, C., Gao, L., Zhang, Y., Jin, X., Wang, M., Wang, Q., Zhao, W., Wu, N., Zhang, Y., Liu, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156110 · Cited by 16

The abnormal expression of circ-ARAP2 promotes ESCC progression through regulating miR-761/FOXM1 axis-mediated stemness and the endothelial–mesenchymal transition

Xu, P., Wang, L., Liu, Q., Gao, P., Hu, F., Xie, X., Lianyong, J., Bi, R., Ding, F., Yang, Q., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03507-3 · Cited by 15

The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases

Hu, X., Liu, X., Khatri, U., & Wu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100958 · Cited by 15

Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy

Peng, M., Ying, Y., Zhang, Z., Liu, L., & Wang, W. (2023) · Cancers · doi:10.3390/cancers15092448 · Cited by 14

Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges

Liu, J., Chao, T., Liu, Y., Chen, G., Zhang, Y., & Xiong, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061706 · Cited by 14

The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside

Zhao, K., Li, X., Feng, Y., Wang, J. M., & Yao, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00559-z · Cited by 14

Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions

Zhao, D., Wen, X., Wu, J., & Chen, F. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102086 · Cited by 14

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations

Ohara, S., Suda, K., & Mitsudomi, T. (2021) · Cells · doi:10.3390/cells10020354 · Cited by 13

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15

Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target

Wang, H., Tang, S., Wu, Q., He, Y., Zhu, W., Xie, X., Qin, Z., Wang, X., Zhou, S., Yao, S., et al. (2024) · National Science Review · doi:10.1093/nsr/nwae392 · Cited by 13

The epigenome and the many facets of cancer drug tolerance

Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy

Voigt, E. M., & Quelle, D. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713596 · Cited by 11

Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs

Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.01.007 · Cited by 14

Single-Cell Transcriptomics Unveils the Dedifferentiation Mechanism of Lung Adenocarcinoma Stem Cells

Pan, Z., Zhang, M., Zhang, F., Pan, H., Li, Y., Shao, Y., Yuan, X. T., Wang, J., & Chen, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010482 · Cited by 11

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

Moonmuang, S., Tantraworasin, A., Orrapin, S., Udomruk, S., Chewaskulyong, B., Pruksakorn, D., & Chaiyawat, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054827 · Cited by 12

Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer

Zhang, C., Wu, B. Z., & Thu, K. L. (2025) · Cancers · doi:10.3390/cancers17040685 · Cited by 12

Kinectin1 depletion promotes EGFR degradation via the ubiquitin-proteosome system in cutaneous squamous cell carcinoma

Ma, J., Ma, S., Zhang, Y., Shen, Y., Huang, L., Lu, T., Wang, L., Wen, Y., & Ding, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04276-5 · Cited by 12

Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity

Jiménez-Castaño, R., & Nieto, M. A. (2026) · Nature Cancer · doi:10.1038/s43018-026-01154-x · Cited by 14

Emerging insights to lung cancer drug resistance

Su, C. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.61 · Cited by 12

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components

Nilsson, M. B., Sun, H., Robichaux, J. P., Diao, L., Xi, Y., Tong, P., Sheng, L., Hofstad, M. E., Kawakami, M., Le, X., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.123 · Cited by 1

Abstract 1960: T790M-independent EGFR TKI resistance is associated with a broad multi-drug resistant phenotype but selective vulnerabilities to spindle assembly complex (SAC) and CDK inhibitors

Nilsson, M. B., Robichaux, J., Sun, H., Tong, P., Diao, L., Hofstad, M. E., Fan, Y.-H., Wang, J., & Heymach, J. V. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1960

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

McGowan, M., Kleinberg, L., Halvorsen, A. R., Helland, Å., & Brustugun, O. T. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.136 · Cited by 65

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma

Shi, R., Farnsworth, D., Febres‐Aldana, C. A., Chow, J. L. M., Sheena, R., Atwal, T., Marti, J. L. G., Li, S., Thomas, K. N., Lee, C.-M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03461-6 · Cited by 13

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 101